Janssen Japan down on end of KHK deal
Janssen Pharmaceutical, a Japanese subsidiary of US health care major Johnson & Johnson, saw a 7% drop in sales year-on-year, on a "shipping basis," for 2008, due to the termination of a co-marketing agreement for Durotep Patch (fentanyl) with Kyowa Hakko Kirin in April.
The subsidiary hopes to achieve 100.0 billion yen ($1.0 billion) in revenue by its 30th anniversary, due to strong performances from: Velcade (bortezomib) in multiple myeloma, up 154% to 6.3 billion yen; tinea unguium drug Itrizole (itriconazole), up 7% to 19.2 billion yen; and Durotep, which was up 2% to 19.0 billion yen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze